Lung Cancer
Conference Coverage
Cardiotoxicity after checkpoint inhibitor treatment seen early, linked to elevated biomarkers
PHILADELPHIA – The findings support monitoring of cardiac biomarkers in the initial phase of checkpoint inhibitor treatment to identify patients...
Conference Coverage
Osimertinib improves survival in advanced NSCLC
BARCELONA – Osimertinib is the first TKI to show a survival advantage over another in advanced non–small cell lung cancer, FLAURA investigators...
Conference Coverage
CheckMate 817: Nivo+ipi shows safety, efficacy across stage IV NSCLC subgroups
BARCELONA – Combination nivolumab and ipilimumab showed good safety and encouraging clinical activity in patients with advanced NSCLC, despite...
Conference Coverage
PACIFIC: Patterns of lung cancer progression suggest role for local ablative therapy
Approximately two-thirds of patients with distant progression had one or two new lesions.
Conference Coverage
Adding radiation to immunotherapy may extend PFS in progressive lung cancer
After a median follow-up of 15.2 months, the disease control rate was 57% with the addition of SBRT for patients with metastatic NSCLC who...
From the Journals
Many institutions exceed recommended radiation doses during lung cancer screening
Allowing any radiologist, rather than a lead radiologist, to establish CT protocols is associated with high likelihood of exceeding ACR dose...
Conference Coverage
IMpower131: Improvement in OS for stage IV NSCLC+high-PD-L1 expression
BARCELONA – Patients in the IMpower131 trial with high PD-L1 expression experienced a clinically meaningful improvement in OS with atezolizumab +...
Conference Coverage
LDCT plus miRNA bolsters prevention efforts
BARCELONA – Adding miRNA testing to LDCT lung cancer screening improves prevention efforts with no detrimental effects in lung cancer detection or...
Conference Coverage
MYSTIC trial analysis IDs mutations prognostic of mNSCLC outcomes
An exploratory analysis of MYSTIC trial specimens shows that mutations in the tumor suppressor KEAP1, STK11, and ARID1a genes in mNSCLC genes have...
Conference Coverage
IASLC survey: Ongoing and intensified molecular testing education needed globally
The top five barriers to the use of molecular testing included cost, quality, access, awareness, and time.